Amneal to Report First Quarter 2022 Results on May 4, 2022

Rhea-AI Summary

Amneal Pharmaceuticals, Inc. (NYSE: AMRX) will announce its first quarter 2022 financial results on May 4, 2022, before the market opens. A conference call and live webcast with investors will occur at 8:30 a.m. Eastern Time the same day. Investors can access the financial results and the webcast on the company’s Investor Relations website. For those wishing to join the call, U.S. participants can dial (844) 200-6205 and international callers can use (929) 526-1599, with access code 874223.

BRIDGEWATER, N.J.--(BUSINESS WIRE)-- Amneal Pharmaceuticals, Inc. (NYSE: AMRX) announced today that the Company will release its first quarter 2022 financial results on Wednesday, May 4, 2022, prior to market open. The Company will host a conference call and live webcast with the investment community at 8:30 a.m. Eastern Time on May 4, 2022.

The financial results and live webcast will be accessible through the Investor Relations section of the Company's website at https://investors.amneal.com.

To access the call through a conference line, dial (844) 200-6205 (in the U.S.) or (929) 526-1599 (international callers). The access code for the call is 874223.

A replay of the conference call will be posted shortly after the call and will be available for seven days. To access the replay, dial (866) 813-9403 (in the U.S.) or +44 (204) 525-0658 (international callers). The access code for the replay is 097886.

About Amneal

Amneal Pharmaceuticals, Inc. (NYSE: AMRX), headquartered in Bridgewater, NJ, is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals, primarily within the United States. The Company has a diverse portfolio of approximately 250 products in its Generics segment and is expanding across a broad range of complex products and therapeutic areas, including injectables and biosimilars. In its Specialty segment, Amneal has a growing portfolio of branded pharmaceutical products focused primarily on central nervous system and endocrine disorders, with a pipeline focused on unmet needs. Through its AvKARE segment, the Company is a distributor of pharmaceuticals and other products for the U.S. federal government, retail, and institutional markets. For more, please visit www.amneal.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220407005096/en/

Anthony DiMeo

Head of Investor Relations

Anthony.DiMeo@amneal.com

Source: Amneal Pharmaceuticals, Inc.

FAQ

When will Amneal Pharmaceuticals release its first quarter 2022 financial results?

Amneal Pharmaceuticals will release its first quarter 2022 financial results on May 4, 2022.

What time is the Amneal Pharmaceuticals conference call on May 4, 2022?

The conference call will take place at 8:30 a.m. Eastern Time on May 4, 2022.

How can I access the Amneal Pharmaceuticals financial results?

Financial results can be accessed through the Investor Relations section of the Amneal Pharmaceuticals website.

What is the access code for the Amneal Pharmaceuticals conference call?

The access code for the conference call is 874223.

How can I listen to the replay of the Amneal Pharmaceuticals conference call?

To listen to the replay, dial (866) 813-9403 in the U.S. or +44 (204) 525-0658 internationally, using access code 097886.